These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 35779586)

  • 1. Immune effects of 17α-hydroxyprogesterone caproate.
    Al-Lami RA
    Am J Obstet Gynecol; 2022 Oct; 227(4):671-675. PubMed ID: 35779586
    [No Abstract]   [Full Text] [Related]  

  • 2. The association between 17-hydroxyprogesterone caproate use and postpartum hemorrhage.
    Miller ES; Sakowicz A; Roy A; Liu LY; Yee LM
    Am J Obstet Gynecol MFM; 2019 May; 1(2):144-147. PubMed ID: 32914089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progesterone is not the same as 17α-hydroxyprogesterone caproate: implications for obstetrical practice.
    Romero R; Stanczyk FZ
    Am J Obstet Gynecol; 2013 Jun; 208(6):421-6. PubMed ID: 23643669
    [No Abstract]   [Full Text] [Related]  

  • 4. 17α-Hydroxyprogesterone Caproate and the Risk of Glucose Intolerance in Pregnancy: A Systematic Review and Meta-analysis.
    Eke AC; Sheffield J; Graham EM
    Obstet Gynecol; 2019 Mar; 133(3):468-475. PubMed ID: 30741815
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The end is where we start from: withdrawal of 17-alpha hydroxyprogesterone caproate to prevent recurrent preterm birth.
    Nelson DB; Herrera CL; McIntire DD; Cunningham FG
    Am J Obstet Gynecol; 2024 Jan; 230(1):1-9. PubMed ID: 37798189
    [No Abstract]   [Full Text] [Related]  

  • 6. Association of 17α-Hydroxyprogesterone Caproate and Risk of Infection.
    Mainiero AD; Rouse DJ; Lopes V; Hughes BL
    Obstet Gynecol; 2015 Jul; 126(1):103-8. PubMed ID: 26241262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regarding 'Gestational age at initiation of 17-alpha hydroxyprogesterone caproate and recurrent preterm birth'.
    Deng Z; Lu D
    Eur J Obstet Gynecol Reprod Biol; 2022 Mar; 270():246. PubMed ID: 35151530
    [No Abstract]   [Full Text] [Related]  

  • 8. Operationalizing 17α-Hydroxyprogesterone Caproate to Prevent Recurrent Preterm Birth: Definitions, Barriers, and Next Steps.
    Stringer EM; Vladutiu CJ; Batra P; Stringer JSA; Menard MK
    Obstet Gynecol; 2016 Dec; 128(6):1397-1402. PubMed ID: 27824772
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Defining the clinical response to 17-alpha hydroxyprogesterone caproate.
    Caritis SN; Hauspurg A; Venkataramanan R; Lemon L
    Am J Obstet Gynecol; 2018 Dec; 219(6):623-625. PubMed ID: 30171841
    [No Abstract]   [Full Text] [Related]  

  • 10. Vaginal progesterone vs intramuscular 17-hydroxyprogesterone caproate for prevention of recurrent preterm birth: a randomized controlled trial.
    Boelig RC; Schoen CN; Frey H; Gimovsky AC; Springel E; Backley S; Berghella V
    Am J Obstet Gynecol; 2022 May; 226(5):722.e1-722.e12. PubMed ID: 35189093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is 17α-hydroxyprogesterone caproate contraindicated in twin gestations?
    Romero R; Conde-Agudelo A
    BJOG; 2015 Jan; 122(1):6-7. PubMed ID: 25280114
    [No Abstract]   [Full Text] [Related]  

  • 12. Prevention of preterm delivery with 17-hydroxyprogesterone caproate: pharmacologic considerations.
    Feghali M; Venkataramanan R; Caritis S
    Semin Perinatol; 2014 Dec; 38(8):516-22. PubMed ID: 25256193
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 17α-hydroxyprogesterone caproate for the prevention of adverse neonatal outcome in multiple pregnancies: a randomized controlled trial.
    Lim AC; Schuit E; Bloemenkamp K; Bernardus RE; Duvekot JJ; Erwich JJHM; van Eyck J; Groenwold RHH; Hasaart THM; Hummel P; Kars MM; Kwee A; van Oirschot CM; van Pampus MG; Papatsonis D; Porath MM; Spaanderman ME; Willekes C; Wilpshaar J; Mol BWJ; Bruinse HW
    Obstet Gynecol; 2011 Sep; 118(3):513-520. PubMed ID: 21860279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 17alpha-hydroxyprogesterone caproate for the prevention of preterm delivery: A cost-effectiveness analysis.
    Odibo AO; Stamilio DM; Macones GA; Polsky D
    Obstet Gynecol; 2006 Sep; 108(3 Pt 1):492-9. PubMed ID: 16946206
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 17-alpha hydroxyprogesterone caproate for preterm birth prevention: Where have we been, how did we get here, and where are we going?
    Manuck TA
    Semin Perinatol; 2017 Dec; 41(8):461-467. PubMed ID: 28947068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A chronicle of the 17-alpha hydroxyprogesterone caproate story to prevent recurrent preterm birth.
    Nelson DB; McIntire DD; Leveno KJ
    Am J Obstet Gynecol; 2021 Feb; 224(2):175-186. PubMed ID: 33035472
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 17-hydroxyprogesterone caproate for twin pregnancy: a double-blind, randomized clinical trial.
    Combs CA; Garite T; Maurel K; Das A; Porto M;
    Am J Obstet Gynecol; 2011 Mar; 204(3):221.e1-8. PubMed ID: 21376161
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of oral Dydrogesterone and 17-α hydroxyprogesterone caprate in the prevention of preterm birth.
    Alizadeh F; Mahmoudinia M; Mirteimoori M; Pourali L; Niroumand S
    BMC Pregnancy Childbirth; 2022 Mar; 22(1):167. PubMed ID: 35232423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 17 α-hydroxyprogesterone caproate (Makena®): a guide to its use in the prevention of preterm birth.
    Hines M; Lyseng-Williamson KA; Deeks ED
    Clin Drug Investig; 2013 Mar; 33(3):223-7. PubMed ID: 23413110
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes With Cerclage Alone Compared With Cerclage Plus 17α-Hydroxyprogesterone Caproate.
    Berghella V; Owen J; Szychowski JM
    Obstet Gynecol; 2017 Feb; 129(2):390-391. PubMed ID: 28121824
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.